Palleon Pharmaceuticals announces issuance of a U.S. Patent for the use of antibody sialidase conjugates
We are always thrilled to see companies adjancing drugs in the field of glycochemistry, just as Palleon Pharmaceuticals. who recently announced patenting engineered human sialidase enzymes that restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and across immune cell types
